0001104659-24-009658.txt : 20240202 0001104659-24-009658.hdr.sgml : 20240202 20240202060207 ACCESSION NUMBER: 0001104659-24-009658 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240202 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zura Bio Ltd CENTRAL INDEX KEY: 0001855644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40598 FILM NUMBER: 24588686 BUSINESS ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-247-0520 MAIL ADDRESS: STREET 1: 4225 EXECUTIVE SQUARE STREET 2: SUITE 600 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: JATT Acquisition Corp DATE OF NAME CHANGE: 20210407 8-K 1 tm244433d1_8k.htm FORM 8-K
false 0001855644 0001855644 2024-02-02 2024-02-02 0001855644 us-gaap:CommonClassAMember 2024-02-02 2024-02-02 0001855644 us-gaap:WarrantMember 2024-02-02 2024-02-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

February 2, 2024

Date of Report (Date of earliest event reported)

 

Zura Bio Limited

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-40598   98-1725736
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

(Address of principal executive offices, including zip code)

 

(702) 757-6133

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share   ZURA   The Nasdaq Stock Market
Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share   ZURAW   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On February 2, 2024, Zura Bio Limited issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information set forth in this Item 7.01 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.		   Description
99.1   Press Release dated February 2, 2024.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 2, 2024

 

  ZURA BIO LIMITED
   
  By: /s/ Kim Davis
    Kim Davis
    Chief Legal Officer

 

 

 EX-99.1 2 tm244433d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Zura Bio Announces Participation at February Investor Conferences

 

Henderson, Nev – February 2, 2024 - Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate at several upcoming conferences in February.

 

Conference Details:

 

Event: Oppenheimer 2024 Winter CEO and Investor Summit

Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in 1x1 investor meetings from February 5 - 8, 2024, in Vail, CO.

 

Event: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Details: Robert Lisicki, President and Chief Operating Officer, will participate in a company presentation and investor 1x1 meetings on February 7 – 8, 2024, in New York, NY. The company presentation is currently scheduled for Wednesday, February 7, 2024 at 3:00 p.m. EST.

 

Event: Oppenheimer 34th Annual Healthcare Life Sciences Conference

Details: Robert Lisicki, President and Chief Operating Officer, and Kiran Nistala, M.D., Ph.D., Chief Medical Officer and Head of Development, will participate in a virtual company presentation and investor 1x1 meetings on February 13 - 14, 2024. The company presentation is currently scheduled for Tuesday, February 13, 2024 at 8:00 a.m. EST.

 

Event: Piper Sandler TSLP Biology Day

Details: Kiran Nistala, M.D., Ph.D., Chief Medical Officer and Head of Development, and Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will be participating in a virtual discussion on thymic stromal lymphopoietin (TSLP) science and its current landscape on Friday, February 23, 2024 at 9:00 – 9:30 a.m. EST.

 

Links for live webcasts and replays, if available, will be posted on the News & Events page in the Investors section of the Zura Bio website. Presentations will be archived on the website for at least 30 days following the event.

 

About Zura Bio

 

Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for ZB-106 (tibulizumab), ZB-168, and ZB-880 (torudokimab) with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders, including systemic sclerosis and other novel indications with unmet needs.

 

 

 

 

Forward-Looking Statements

 

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” “strategy,” “future,” “opportunity,” “would,” “seem,” “seek,” “outlook” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

 

Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” sections of Zura Bio’s recent filings with the SEC. These filings would identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Many of these factors are outside Zura Bio’s control and are difficult to predict. Many factors could cause actual future events to differ from the forward-looking statements in this communication, including but not limited to: (1) the outcome of any legal proceedings that may be instituted against Zura Bio; (2) volatility in the price of Zura Bio’s securities; (3) the ability of Zura Bio to successfully conduct research and development activities, grow and manage growth profitably, maintain relationships with customers and suppliers, and retain key employees; (4) the ongoing costs relating to operating as a public company; (5) changes in the applicable laws or regulations; (6) the possibility that Zura Bio may be adversely affected by other economic, business, and/or competitive factors; (7) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Zura Bio operates; (8) the potential inability of Zura Bio to raise additional capital needed to pursue its business objectives or to achieve efficiencies regarding other costs; (9) the enforceability of Zura Bio’s intellectual property, including its patents, and the potential infringement on the intellectual property rights of others, cyber security risks or potential breaches of data security; and (10) other risks and uncertainties described in the registration statement on Form S-1 filed with the SEC on June 14, 2023, and such other documents filed by Zura Bio from time to time with the SEC. These risks and uncertainties may be amplified by the COVID-19 pandemic or other unanticipated global disruption events, which may continue to cause economic uncertainty. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Zura Bio gives no assurance that it will achieve its expectations. Zura Bio does not undertake or accept any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, or should circumstances change, except as otherwise required by securities and other applicable laws.

 

Contacts

 

Megan K. Weinshank

Head of Investor Relations

IR@zurabio.com

 

Lee M. Stern

Meru Advisors

lstern@meruadvisors.com

 

 

 GRAPHIC 3 tm244433d1_ex99-1img001.jpg GRAPHIC begin 644 tm244433d1_ex99-1img001.jpg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zura-20240202.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 zura-20240202_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 zura-20240202_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Class A [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] UnitsMember EX-101.PRE 7 zura-20240202_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 02, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 02, 2024
Entity File Number 001-40598
Entity Registrant Name Zura Bio Limited
Entity Central Index Key 0001855644
Entity Tax Identification Number 98-1725736
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One 1489 W. Warm Springs Rd
Entity Address, Address Line Two #110
Entity Address, City or Town Henderson
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89014
City Area Code 702
Local Phone Number 757-6133
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A Ordinary Shares, par value $0.0001 per share
Trading Symbol ZURA
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
Trading Symbol ZURAW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://zurabio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm244433d1_8k.htm zura-20240202.xsd zura-20240202_def.xml zura-20240202_lab.xml zura-20240202_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm244433d1_8k.htm": { "nsprefix": "zura", "nsuri": "http://zurabio.com/20240202", "dts": { "inline": { "local": [ "tm244433d1_8k.htm" ] }, "schema": { "local": [ "zura-20240202.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "zura-20240202_def.xml" ] }, "labelLink": { "local": [ "zura-20240202_lab.xml" ] }, "presentationLink": { "local": [ "zura-20240202_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://zurabio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm244433d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm244433d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://zurabio.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://zurabio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001104659-24-009658-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-009658-xbrl.zip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end XML 18 tm244433d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001855644 2024-02-02 2024-02-02 0001855644 us-gaap:CommonClassAMember 2024-02-02 2024-02-02 0001855644 us-gaap:WarrantMember 2024-02-02 2024-02-02 iso4217:USD shares iso4217:USD shares false 0001855644 8-K 2024-02-02 Zura Bio Limited E9 001-40598 98-1725736 1489 W. Warm Springs Rd #110 Henderson NV 89014 702 757-6133 false false false false Class A Ordinary Shares, par value $0.0001 per share ZURA NASDAQ Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share ZURAW NASDAQ true false